Hence, CD109, KIAA0125, and HOPX seem to be involved in or are surrogates of cellular processes that reflect a more aggressive disease independent of the fact that their expression levels might be directly affected by RUNX1 alterations in AML. This evidence concerns the gene HOPX and acute myeloid leukemia.